呼吸器感染症に対するpazufloxacinの基礎的・臨床的検討

DOI 参考文献12件

書誌事項

タイトル別名
  • Fundamental and clinical study of pazufloxacin in the respiratory tract infection

この論文をさがす

抄録

We evaluated the usefulness of pazufloxacin (PZFX), a new quinolone derivative, in respiratory tract infections. The MIC50 of PZFX for methicillin-sensitive Staphylococcus aureus was 0.39μg/ml. It was 12.5μg/ml for methicillin-resistant S. aureus, 3.13μg/ml for Streptococcus pneumoniae, 0.013μg/ml for Haemophilus influenzae, 0.025μg/ml for Moraxella catarrhalis and 1.56μg/ml for Pseudomonas aeruginosa.<BR>The activity was comparable with or superior to that of ofloxacin (OFLX).<BR>The pharmacokinetics of PZFX were studied in two patients. The maximum sputum levels during a 200mg oral administration three times per day were 0.72μg/g and 2.27μg/g.<BR>Twelve patients with lower respiratory tract infections were studied for clinical evaluation of PZFX. PZFX was given orally at 300-600 mg per day for 3-7 days. The causative organisms were S. pneumoniae (2 cases), H. influenzae (3 cases), M. catarrhalis (1 case) and P. aeruginosa (2 cases). The rate of clinical response was 81.8%. Two strains of S. pneumoniae and 2 strains of P. aeruginosa were not eliminated in sputum samples. Diarrhea was observed in one case.<BR>We concluded that PZFX is a useful oral antimicrobial agent for the treatment of respiratory tract infections.

収録刊行物

参考文献 (12)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ